

Claims

1. A recombinant herpesvirus, which contains a rep and a cap gene derived from adeno-associated viruses (AAVs) and operatively linked to an expression control sequence.
2. ~~A recombinant herpesvirus as claimed in claim 1, which does not exhibit any reversion to the wild type.~~
3. A recombinant herpesvirus as claimed in claim 1 ~~or 2~~, which additionally comprises a reporter gene.
4. A recombinant herpesvirus as claimed in ~~one of the preceding claims~~, which is selected from the group of Herpesviridae comprising herpes simplex virus (HSV), cytomegalovirus (CMV), pseudorabies virus (PRV) and Epstein-Barr virus (EBV) and other ~~members of the herpesvirus family~~.
5. A recombinant herpesvirus as claimed in claim 4, which is a herpes simplex virus (HSV).
6. A recombinant herpesvirus as claimed in claim 5, which is the HSV-1 mutant 1802.
7. ~~A recombinant herpesvirus as claimed in one of the preceding claims, which is a mutant which is completely or partially replication-deficient.~~
8. A recombinant herpesvirus as claimed in one of the preceding claims, wherein the insertion does not encompass the complete AAV ITR sequence.
9. A recombinant herpesvirus as claimed in ~~one of the preceding claims~~, wherein the AAV rep gene and the

Sub B2
AAV cap gene are inserted in the U_L or the U_S region of the herpesvirus.

a
5 10. A process for preparing a recombinant herpesvirus as claimed in ~~one of claims 1 to 9~~ ^{claim 1}, wherein the AAV rep gene and the AAV cap gene are stably integrated into the genome of a herpesvirus.

10 11. The process as claimed in claim 10, wherein the rep gene and the cap gene are integrated into the herpes genome by restriction cleavage/ligation or by homologous recombination.

a
15 12. The process as claimed in claim 10 ~~or 11~~, wherein use is made of an HSV mutant which possesses a unique restriction site.

SUB C3
20 13. The process as claimed in claim 11, wherein use is made of an HSV mutant which is completely or partially replication-deficient.

25 14. A nucleic acid which comprises the helper functions of a herpesvirus genome which are required for replicating AAV viruses and, inserted therein, a rep gene and a cap gene derived from adeno-associated viruses (AAVs), in each case operatively linked to an expression control sequence.

Sub B3
30 15. A vector, which comprises a nucleic acid as claimed in claim 14.

a
35 16. A viral composition which comprises a recombinant ~~herpesvirus~~ ^{Claim 1} as claimed in ~~one of claims 1 to 9~~.

17. A composition as claimed in claim 16, which is free of wild-type herpesvirus.

18. ~~A process for preparing infectious AAV vector preparations, comprising the steps of:~~
a) preparing a viral vector which is based on adeno-associated viruses (AAVs),
b) preparing a recombinant herpesvirus as claimed in ~~one of claims 1 to 9,~~ *claim 1*
c) introducing the AAV vector from (a) and the recombinant herpesvirus from (b) into a cell,
d) replicating the AAV vector, and
e) obtaining an infectious AAV vector preparation.

19. The process as claimed in ~~claim 18,~~ wherein the AAV vector and the recombinant herpesvirus are introduced into the cell by infection.

20. The process as claimed in ~~claim 18 or 19,~~ wherein an encapsulated rAAV preparation is obtained.

21. The process as claimed in ~~one of claims 18 to 20,~~ *claim 18* wherein use is made of a replicatable recombinant herpesvirus.

22. The process as claimed in ~~claims 18 to 20,~~ *claim 18* wherein use is made of a non-replicatable recombinant herpesvirus.

23. ~~A cell, which contains a recombinant herpesvirus as claimed in one of claims 1 to 9 or a vector as claimed in claim 15.~~ *claim 1*

24. A cell as claimed in ~~claim 23,~~ wherein the recombinant herpesvirus or the vector has been introduced by infection.

25. A cell as claimed in ~~claim 23 or 24,~~ which additionally contains a recombinant AAV vector.

26. A cell as claimed in claim 25, wherein the AAV vector contains a heterologous DNA insert which encodes a therapeutically active polypeptide.

9 27. A cell as claimed in ~~one of claims 23 to 26~~, which is a BHK cell, a Vero cell or a HeLa cell.

10 28. A process for producing infectious AAV vector preparations, with an AAV vector and a helper virus being introduced into a cell, the AAV vector being replicated and an infectious AAV vector preparation being obtained from the cell and/or the culture supernatant, wherein the AAV vector and the helper virus are introduced into the cell by infection.

15

add a'

add b'